Semaglutide

FDA-approved titration starts at 0.25mg weekly for the first 4 weeks, then escalates monthly (0.5mg, 1mg, 1.7mg, 2.4mg for weight management; lower for diabetes indications). **The 0.25mg starting dose is a tolerability dose, not a therapeutic dose** - starting higher or skipping the 4-week observation window materially increases severe side effects. The 4-week observation window at each dose is the published trial protocol. The dose-limiting side effects - nausea, GI discomfort, fatigue, mild satiety changes - appear within this window and typically improve as the body adapts. Most patients reach effective therapeutic doses (1.7–2.4mg) within 4–5 months. **Sensitivity-adapted starts:** patients with prior GLP-1 side effects, low body mass, GI sensitivity history, or older first-time users may hold 0.25mg for 8 weeks before advancing - physician discretion. Maximum tolerated dose is the target, not maximum approved dose.

Semaglutide has the most established cardiovascular safety profile of any compound Vivre carries. The SELECT trial (n=17,604, 5+ years) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in patients with established cardiovascular disease and overweight/obesity. Mean resting HR increases of approximately 2–3 BPM are documented and considered acceptable given the net cardiovascular benefit. Baseline HR/BP measurement is still standard practice; persistent symptoms warrant physician contact.

The STEP-4 trial demonstrated that patients who switched from semaglutide to placebo after 20 weeks regained approximately two-thirds of their lost weight over the following 48 weeks. The drug is a tool - not the foundation. Sustainable outcomes require: a moderate caloric deficit (not extreme - the appetite suppression already produces a substantial deficit), **adequate protein (target 1.6–2.0 g/kg body weight daily during active weight loss to preserve lean mass; patients with very low baseline protein intake can begin at 1.25–1.5 g/kg as a floor and progress upward)**, micronutrient-dense food, resistance training at least 2× weekly, and adequate sleep. Semaglutide makes the foundation easier to maintain - it does not replace it. Long-term sustainability planning is part of the protocol from day one.

Semaglutide delays gastric emptying - the satiety mechanism that drives effectiveness is the same mechanism producing nausea when meals are too large or too fatty. Practical consequence: smaller meals, eaten slowly, with attention to early-satiety signals. **A note on carbonated water:** despite community-practice mentions of carbonation easing fullness, current clinical guidance points the opposite direction - trapped CO2 from carbonation amplifies bloating, distension, and reflux when gastric emptying is already delayed. Standard physician advice is to avoid carbonated beverages during titration and at higher doses. Still water, ginger tea, peppermint tea, or warm water are the better choices. **Hydration pattern:** sip throughout the day rather than gulping at meals. **Electrolyte awareness:** sodium, potassium, and magnesium loss accelerates when appetite suppression reduces food intake. Persistent fatigue, dizziness, or muscle cramps often resolve with light electrolyte supplementation - discuss with your physician.

Reconstituted peptides degrade over time. Industry-standard data for bacteriostatic-water reconstituted GLP-1 agonists places usable potency at approximately 4 weeks refrigerated, with measurable degradation accumulating beyond that - aggregation, oxidation, and conformational drift are the relevant pathways. Once you mix the vial, every additional day in solution is degradation, even at proper refrigeration. Vivre sizes semaglutide vials at 10–20mg specifically to match a real titration or maintenance window of 3–6 weeks per vial (semaglutide is dosed in lower mg amounts than tirzepatide and retatrutide, so the vial consumption profile differs). The product you inject toward the end of a vial is at near-peak potency rather than degraded by a long shelf life in solution. The trade-off is more frequent shipments versus larger research-vendor vials - but those only work at peak potency for the first few weeks of a longer consumption window. Sizing matters for dose-to-dose consistency.

Vivre recommends cycling semaglutide on a 3-months-on, 1-month-off cadence under physician supervision. The reasoning: (a) extended continuous GLP-1 receptor activation may produce receptor downregulation over time, and a planned washout helps preserve responsiveness; (b) the long-term digestive-tract effects of years of continuous gastric-emptying delay are not fully characterised - semaglutide has the longest established record in this class but post-marketing surveillance still extends only a few years for the weight-management indication; (c) the off-month gives the body a recovery window, lets patients confirm lifestyle changes are sustaining benefit independent of the drug, and resets tolerance for the next on-cycle. Honest framing: Phase 3 trials (SUSTAIN, STEP) ran continuous dosing - cycling is not a clinical-trial-validated protocol but a mechanistically-reasoned physician practice. SELECT trial cardiovascular-benefit data also reflects continuous dosing. Patients using semaglutide primarily for cardiovascular-risk reduction or active T2DM management have physician guidance to maintain continuous dosing.